Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 11–12
HOS-209751 · Präparat HOS-154375
11
Drug/Substance Class or Drug interaction effect Recommendations concerning co-
Name administration
The effect on tacrolimus
blood concentrations may
remain for several days after
co-administration is
completed.
Moderate or weak CYP3A4 May increase tacrolimus Monitor tacrolimus whole blood
inhibitors: whole blood trough trough concentrations frequently,
antifungal agents (e.g., concentrations and increase starting within the first few days
fluconazole, isavuconazole, the risk of serious adverse of co-administration. Reduce
clotrimazole, miconazole), reactions (e.g., neurotoxicity, tacrolimus dose if needed [see
the macrolide antibiotics QT prolongation) [see section 4.2]. Monitor renal
(e.g., azithromycin), calcium section 4.4]. A rapid increase function, ECG for QT
channel blockers (e.g., in tacrolimus level may prolongation, and other side
nifedipine, nicardipine, occur. effects closely.
diltiazem, verapamil),
amiodarone, danazol,
ethinylestradiol, lansoprazole,
omeprazole, the HCV
antivirals elbasvir/grazoprevir
and glecaprevir/pibrentasvir,
the CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib, crizotinib
and imatinib and (Chinese)
herbal remedies containing
extracts of Schisandra
sphenanthera
In vitro the following May increase tacrolimus Monitor tacrolimus whole blood
substances have been shown whole blood trough trough concentrations and reduce
to be potential inhibitors of concentrations and increase tacrolimus dose if needed [see
tacrolimus metabolism: the risk of serious adverse section 4.2].
bromocriptine, cortisone, reactions (e.g., neurotoxicity, Monitor renal function, ECG for
dapsone, ergotamine, QT prolongation) [see QT prolongation, and other side
gestodene, lidocaine, section 4.4]. effects closely.
mephenytoin, midazolam,
nilvadipine, norethisterone,
quinidine, tamoxifen
Strong CYP3A4 inducers: May decrease tacrolimus It is recommended that
rifampicin, phenytoin whole blood trough concomitant use should be
carbamazepine, apalutamide, concentrations and increase avoided. If unavoidable, patients
enzalutamide, mitotane or St. the risk of rejection [see may require an increase in
John’s wort (Hypericum section 4.4]. tacrolimus dose. Changes in
perforatum) Maximal effect on tacrolimus tacrolimus dose should be
blood concentrations may be individualized and adjusted as
achieved 1-2 weeks after co- needed based on tacrolimus
administration. The effect trough concentrations, which
may remain 1-2 weeks after should be assessed at initiation,
completion of the treatment. monitored frequently throughout
(starting within the first few days)
and re-evaluated on and after
completion of the CYP3A4
inducer. After use of the CYP3A4
inducer has ended, tacrolimus
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) diltiazem (HOS-086288) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) cortisone (HOS-114161) nicardipine (HOS-090619) pibrentasvir (HOS-086298) lidocaine (HOS-108866) carbamazepine (HOS-085618) crizotinib (HOS-116818) apalutamide (HOS-086212) tamoxifen (HOS-088380) quinidine (HOS-085593) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) mephenytoin (HOS-109801) calcium (HOS-085615) imatinib (HOS-110212) grazoprevir (HOS-108815) danazol (HOS-085473) mitotane (HOS-112479) fluconazole (HOS-087945) bromocriptine (HOS-090620) nilvadipine (HOS-116826) gestodene (HOS-116824) ergotamine (HOS-086154) amiodarone (HOS-085596) tyrosine (HOS-108875) dapsone (HOS-088141) phenytoin (HOS-084531) enzalutamide (HOS-116829) nilotinib (HOS-086218) miconazole (HOS-115630) midazolam (HOS-086167) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 1e7cc303a6d0d182851c23281c6a79a17f96d714a9cddc0ab3d6ada78ab947ab · Zeichen 6985–10993 im Abschnitt
Wechselwirkungen · Enyglid
Enyglid 0.5 mg tablets Enyglid 1 mg tablets Enyglid 2 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-210679 · Präparat HOS-154563
The following substances may reduce the hypoglycaemic effect of repaglinide:
Oral contraceptives, rifampicin, barbiturates, carbamazepine, thiazides, corticosteroids, danazol,
thyroid hormones and sympathomimetics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) danazol (HOS-085473)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-05T16:50:00Z · SHA-256 12b8cb591a06737df18eb1bbe30d3ed0dd1a0bc83bd3555d39ff6f7b72982ce3 · Passage 86c9a7423d143e3e6a9fb744b9e4a154c3278054f86cd2669ee5db3d2bf00d29 · Zeichen 6995–7209 im Abschnitt
Wechselwirkungen · Repaglinide Krka
Repaglinide Krka 0.5 mg tablets Repaglinide Krka 1 mg tablets Repaglinide Krka 2 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-210713 · Präparat HOS-154571
The following substances may reduce the hypoglycaemic effect of repaglinide:
Oral contraceptives, rifampicin, barbiturates, carbamazepine, thiazides, corticosteroids, danazol,
thyroid hormones and sympathomimetics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) danazol (HOS-085473)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-04T16:40:00Z · SHA-256 750cebf2c4f53148860d7f38c6b2067d5b0aa0233a26f1dad391b0ac23efb1ce · Passage 86c9a7423d143e3e6a9fb744b9e4a154c3278054f86cd2669ee5db3d2bf00d29 · Zeichen 6995–7209 im Abschnitt
Wechselwirkungen · Repaglinide Teva
Repaglinide Teva 0.5 mg tablets Repaglinide Teva 1 mg tablets Repaglinide Teva 2 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-210748 · Präparat HOS-154579
The following substances may reduce the hypoglycaemic effect of repaglinide:
Oral contraceptives, rifampicin, barbiturates, carbamazepine, thiazides, corticosteroids, danazol,
thyroid hormones and sympathomimetics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) danazol (HOS-085473)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-11T17:40:00Z · SHA-256 7ea88aaeb62655814b4cbb82e87f581c1d76d8e897c814045f52ed8ce0706612 · Passage 86c9a7423d143e3e6a9fb744b9e4a154c3278054f86cd2669ee5db3d2bf00d29 · Zeichen 7349–7563 im Abschnitt
Wechselwirkungen · Revolade
Revolade 12.5 mg film-coated tablets Revolade 25 mg film-coated tablets Revolade 50 mg film-coated tablets Revolade 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-122098 · Präparat HOS-095473
Medicinal products used in the treatment of ITP in combination with eltrombopag in clinical studies
included corticosteroids, danazol, and/or azathioprine, intravenous immunoglobulin (IVIG), and anti-
D immunoglobulin. Platelet counts should be monitored when combining eltrombopag with other
medicinal products for the treatment of ITP in order to avoid platelet counts outside of the
recommended range (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): danazol (HOS-085473) azathioprine (HOS-089001)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-26T10:21:00Z · SHA-256 3912609780c75b6cf657bad81a36f25e9a4985d64364fb3ab11f095445db8751 · Passage 575afdc97dd8a980ac37c5ebf558df5107ade9c72f8c5d86bb28ed7282a719f0 · Zeichen 5191–5613 im Abschnitt
Wechselwirkungen · Revolade
Revolade 25 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 54
HOS-122174 · Präparat HOS-095473
Medicinal products used in the treatment of ITP in combination with eltrombopag in clinical studies
included corticosteroids, danazol, and/or azathioprine, intravenous immunoglobulin (IVIG), and anti-
D immunoglobulin. Platelet counts should be monitored when combining eltrombopag with other
medicinal products for the treatment of ITP in order to avoid platelet counts outside of the
recommended range (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): danazol (HOS-085473) azathioprine (HOS-089001)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-26T10:21:00Z · SHA-256 3912609780c75b6cf657bad81a36f25e9a4985d64364fb3ab11f095445db8751 · Passage 575afdc97dd8a980ac37c5ebf558df5107ade9c72f8c5d86bb28ed7282a719f0 · Zeichen 5247–5669 im Abschnitt
Wechselwirkungen · Tresiba
Tresiba 100 units/mL FlexTouch solution for injection in pre-filled pen Tresiba 200 units/mL FlexTouch solution for injection in pre-filled pen Tresiba 100 units/mL FlexPen solution for injection in pre-filled pen Tresiba 100 units/mL Penfill solution for injection in cartridge · Abschnitt 4.5 · PDF-Seite 6–7
HOS-126565 · Präparat HOS-096277
6
The following substances may increase the insulin requirement
Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth
hormone and danazol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): danazol (HOS-085473)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-27T15:30:00Z · SHA-256 b4c099eb5b8b3565c60749a59b5111f9719658ee1e926d19ddcb8806358606fc · Passage 3da8b7879c4f972590010368aa7a7e8e96cec9b902771c6ae1e699aca5518019 · Zeichen 404–581 im Abschnitt
Wechselwirkungen · Ryzodeg
Ryzodeg 100 units/mL FlexTouch solution for injection in pre-filled pen Ryzodeg 100 units/mL FlexPen solution for injection in pre-filled pen Ryzodeg 100 units/mL Penfill solution for injection in cartridge · Abschnitt 4.5 · PDF-Seite 6
HOS-126587 · Präparat HOS-096285
The following substances may increase the insulin requirement
Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth
hormone and danazol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): danazol (HOS-085473)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-05-13T01:00:00Z · SHA-256 df86c897629e7225a3f88c7dfc6b236d532d632db8a5b3a5204db17fb07d7e2e · Passage 045e6b8e26348c4e8ee823ed3883bc71fcce26c663b875f3bb4a1e34920eafc7 · Zeichen 352–526 im Abschnitt
Gegenanzeigen · Cholib
Cholib 145 mg/20 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 3
HOS-126950 · Präparat HOS-096355
• Hypersensitivity to the active substances, peanut, soya or to any of the excipients listed in
section 6.1 (see also section 4.4)
• Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen
• Active liver disease or unexplained persistent elevations of serum transaminases
• Known gallbladder disease
• Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe
hypertriglyceridaemia
• Moderate to severe renal insufficiency (estimated glomerular filtration rate
< 60 mL/min/1.73 m2)
• Concomitant administration of potent CYP3A4 inhibitors (agents that increase AUC
approximately 5 fold or greater) (e.g. itraconazole, ketoconazole, posaconazole, voriconazole,
HIV protease inhibitors (e.g. nelfinavir), boceprevir, telaprevir, erythromycin, clarithromycin,
telithromycin, nefazodone, and medicinal products containing cobicistat) (see sections 4.4 and
4.5)
• Concomitant administration of gemfibrozil, ciclosporin, or danazol (see sections 4.4 and 4.5)
• Concomitant administration of glecaprevir/ pibrentasvir (see section 4.5)
• Paediatric population (age below 18 years)
• Pregnancy and breast-feeding (see section 4.6)
• Personal history of myopathy and/or rhabdomyolysis with statins and/or fibrates or confirmed
creatine phosphokinase elevation above 5 times the upper limit of normal (ULN) under previous
statin treatment (see section 4.4)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoprofen (HOS-089671) nefazodone (HOS-084519) nelfinavir (HOS-084520) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) cobicistat (HOS-088111) creatine (HOS-123819) gemfibrozil (HOS-088403) glecaprevir (HOS-086297) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T10:28:00Z · SHA-256 348750d8a2030faed77c9c061fe6342a446d1448175630ef5f5390d9ff5afaad · Passage 01cd865d152730ea7f87e81073b6bc3ccb3f2ff3a9e8e7ee83649a48ba092bdb · Zeichen 0–1506 im Abschnitt
Gegenanzeigen · Cholib
Cholib 145 mg/40 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 25
HOS-127022 · Präparat HOS-096355
• Hypersensitivity to the active substances, peanut, soya or to any of the excipients listed in
section 6.1 (see also section 4.4)
• Known photoallergy or phototoxic reaction during treatment with fibrates or ketoprofen
• Active liver disease or unexplained persistent elevations of serum transaminases
• Known gallbladder disease
• Chronic or acute pancreatitis with the exception of acute pancreatitis due to severe
hypertriglyceridaemia
• Moderate to severe renal insufficiency (estimated glomerular filtration rate
< 60 mL/min/1.73 m2)
• Concomitant administration of potent CYP3A4 inhibitors (agents that increase AUC
approximately 5 fold or greater) (e.g. itraconazole, ketoconazole, posaconazole, voriconazole,
HIV protease inhibitors (e.g. nelfinavir), boceprevir, telaprevir, erythromycin, clarithromycin,
telithromycin, nefazodone, and medicinal products containing cobicistat) (see sections 4.4 and
4.5)
• Concomitant administration of gemfibrozil, ciclosporin, or danazol (see sections 4.4 and 4.5)
• Concomitant administration of glecaprevir, pibrentasvir, elbasvir or grazoprevir (see section
4.5)
• Paediatric population (age below 18 years)
• Pregnancy and breast-feeding (see section 4.6)
• Personal history of myopathy and/or rhabdomyolysis with statins and/or fibrates or confirmed
creatine phosphokinase elevation above 5 times the upper limit of normal (ULN) under previous
statin treatment (see section 4.4)
Concomitant administration of amiodarone, verapamil, amlodipine or diltiazem (see section 4.5)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) ketoprofen (HOS-089671) nefazodone (HOS-084519) elbasvir (HOS-108814) nelfinavir (HOS-084520) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) cobicistat (HOS-088111) amlodipine (HOS-086287) creatine (HOS-123819) gemfibrozil (HOS-088403) glecaprevir (HOS-086297) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) danazol (HOS-085473) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) amiodarone (HOS-085596) posaconazole (HOS-085622) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T10:28:00Z · SHA-256 348750d8a2030faed77c9c061fe6342a446d1448175630ef5f5390d9ff5afaad · Passage b3e383eea6addd5e17e74e7e066bd16291ed5af47e0e656fd20c321af353dadc · Zeichen 0–1610 im Abschnitt
Wechselwirkungen · Cholib
Cholib 145 mg/20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-126958 · Präparat HOS-096355
7
Danazol
The risk of myopathy and rhabdomyolysis is increased by concomitant administration of danazol with
simvastatin. The dose of simvastatin should not exceed 10 mg daily in patients taking danazol.
Therefore, the co-administration of Cholib with danazol is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): danazol (HOS-085473)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T10:28:00Z · SHA-256 348750d8a2030faed77c9c061fe6342a446d1448175630ef5f5390d9ff5afaad · Passage fb1b96c04d26258c70ba6ebd7d0b2ed8f6855db530ab27019ed834d2f39b566a · Zeichen 1772–2070 im Abschnitt
Wechselwirkungen · Cholib
Cholib 145 mg/20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-126998 · Präparat HOS-096355
Interacting substances Prescribing recommendations
Potent CYP 3A4 inhibitors:
Itraconazole
Ketoconazole
Fluconazole
Posaconazole
Erythromycin Contraindicated with Cholib
Clarithromycin
Telithromycin
HIV protease inhibitors (e.g. nelfinavir)
Nefazodone
Cobicistat
Danazol
Contraindicated with Cholib
Ciclosporin
Gemfibrozil, Other statins and fibrates Contraindicated with Cholib
Amiodarone
Verapamil Do not exceed one Cholib 145 mg/20 mg per
Diltiazem day, unless clinical benefit outweigh the risk
Amlodipine
Elbasvir Do not exceed one Cholib 145 mg/20 mg per
Grazoprevir day
Glecaprevir
Contraindicated with Cholib
Pibrentasvir
Avoid with Cholib unless clinical benefit
Niacin (nicotinic acid) ≥ 1 g/day
outweigh the risk
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) nelfinavir (HOS-084520) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) cobicistat (HOS-088111) amlodipine (HOS-086287) gemfibrozil (HOS-088403) glecaprevir (HOS-086297) niacin (HOS-126975) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amiodarone (HOS-085596) posaconazole (HOS-085622) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T10:28:00Z · SHA-256 348750d8a2030faed77c9c061fe6342a446d1448175630ef5f5390d9ff5afaad · Passage e0d38b712e1242faa215e464aecc01b778cbd894151f3fb6e0a8a225fb75b5e1 · Zeichen 10739–11977 im Abschnitt
Wechselwirkungen · Cholib
Cholib 145 mg/40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-127030 · Präparat HOS-096355
Danazol
The risk of myopathy and rhabdomyolysis is increased by concomitant administration of danazol with
simvastatin. The dose of simvastatin should not exceed 10 mg daily in patients taking danazol.
Therefore, the co-administration of Cholib with danazol is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): danazol (HOS-085473)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T10:28:00Z · SHA-256 348750d8a2030faed77c9c061fe6342a446d1448175630ef5f5390d9ff5afaad · Passage 1d4e102a34554dd7ca7f2064fa0e11fcc02472b703b8c7bfcc755bd8725af9bd · Zeichen 1719–2014 im Abschnitt
Wechselwirkungen · Cholib
Cholib 145 mg/40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 32
HOS-127062 · Präparat HOS-096355
Interacting substances Prescribing recommendations
Potent CYP 3A4 inhibitors:
Itraconazole
Ketoconazole
Fluconazole
Posaconazole
Erythromycin Contraindicated with Cholib
Clarithromycin
Telithromycin
HIV protease inhibitors (e.g. nelfinavir)
Nefazodone
Cobicistat
Danazol
Contraindicated with Cholib
Ciclosporin
Gemfibrozil, Other statins and fibrates Contraindicated with Cholib
Amiodarone
Verapamil
Contraindicated with Cholib 145 mg/40 mg
Diltiazem
Amlodipine
Elbasvir
Contraindicated with Cholib 145 mg/40 mg
Grazoprevir
Glecaprevir
Contraindicated with Cholib
Pibrentasvir
Avoid with Cholib unless clinical benefit
outweigh the risk
Niacin (nicotinic acid) ≥ 1 g/day
Monitor patients for any signs and symptoms of
muscle pain, tenderness or weakness
Patients should be closely monitored.
Fusidic acid Temporary suspension of Cholib treatment may
be considered
Grapefruit juice Avoid when taking Cholib
Adjust the dose of these oral anticoagulants
Vitamin K antagonists
according to INR monitoring
Monitor HDL-C and stop either therapy
Glitazones
(glitazone or Cholib) if HDL-C is too low
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) nelfinavir (HOS-084520) protease (HOS-085623) fusidic acid (HOS-086146) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) cobicistat (HOS-088111) vitamin K (HOS-091176) amlodipine (HOS-086287) gemfibrozil (HOS-088403) glecaprevir (HOS-086297) grapefruit juice (HOS-088787) niacin (HOS-126975) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) clarithromycin (HOS-084517) erythromycin (HOS-084514) amiodarone (HOS-085596) posaconazole (HOS-085622) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T10:28:00Z · SHA-256 348750d8a2030faed77c9c061fe6342a446d1448175630ef5f5390d9ff5afaad · Passage 6d5c5fec1da2b5e3bb3b7b5c49df8bee2d9cf49df82aef774324124447b7a727 · Zeichen 10741–12812 im Abschnitt
Wechselwirkungen · Xultophy
Xultophy 100 units/mL + 3.6 mg/mL solution for injection. · Abschnitt 4.5 · PDF-Seite 6
HOS-128055 · Präparat HOS-096509
The following substances may increase the Xultophy requirement:
Oral contraceptives, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth
hormones and danazol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): danazol (HOS-085473)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-11-28T15:25:00Z · SHA-256 a7d7c9b9466581209cafd8573496579754b87e259d5bc2843f330d525f02ca26 · Passage ec5020d8500e21dd4c36f04f2233bb8b01f8278b49b40cc546eccf687b61fb56 · Zeichen 429–606 im Abschnitt
Wechselwirkungen · Abasaglar (previously Abasria)
ABASAGLAR 100 units/mL solution for injection in a cartridge · Abschnitt 4.5 · PDF-Seite 6
HOS-130164 · Präparat HOS-096865
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens, progestogens, phenothiazine derivatives,
somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol,
terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and
olanzapine) and protease inhibitors.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) protease (HOS-085623) diazoxide (HOS-088588) danazol (HOS-085473) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-13T13:04:00Z · SHA-256 8a48895fa1a195b1b88589b8cd0ee2e2b7b31cd9b013ed1703865e2f5891fd58 · Passage c204b8fad07c84795316d1781908e1ee1b5a381595932c1a6a0058675104930f · Zeichen 473–885 im Abschnitt
Wechselwirkungen · Abasaglar (previously Abasria)
ABASAGLAR 100 units/mL KwikPen solution for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 20
HOS-130204 · Präparat HOS-096865
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens, progestogens, phenothiazine derivatives,
somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol,
terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and
olanzapine) and protease inhibitors.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) protease (HOS-085623) diazoxide (HOS-088588) danazol (HOS-085473) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-13T13:04:00Z · SHA-256 8a48895fa1a195b1b88589b8cd0ee2e2b7b31cd9b013ed1703865e2f5891fd58 · Passage c204b8fad07c84795316d1781908e1ee1b5a381595932c1a6a0058675104930f · Zeichen 473–885 im Abschnitt
Wechselwirkungen · Suliqua
Suliqua 100 units/ml + 50 micrograms/ml solution for injection in pre-filled pen Suliqua 100 units/ml + 33 micrograms/ml solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 7
HOS-136758 · Präparat HOS-097920
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol,
diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives,
somatropin, sympathomimetic medicinal products (e.g., epinephrine [adrenaline], salbutamol,
terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g., clozapine and
olanzapine) and protease inhibitors.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): olanzapine (HOS-085937) protease (HOS-085623) diazoxide (HOS-088588) danazol (HOS-085473) somatropin (HOS-088591) epinephrine (HOS-088592) clozapine (HOS-086149) terbutaline (HOS-085475) isoniazid (HOS-088590) glucagon (HOS-088589)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:17:00Z · SHA-256 dc49151049b984e91c1de4b6624055f9c88998d89821408c31acf9bbdf9d1734 · Passage 192500b863b13435d4abfa5e828836106445012113b370397ddfddd94fa2cbbc · Zeichen 603–1020 im Abschnitt
Wechselwirkungen · Tacforius
Tacforius 0.5 mg prolonged-release hard capsules Tacforius 1 mg prolonged-release hard capsules Tacforius 3 mg prolonged-release hard capsules Tacforius 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 11–12
HOS-139158 · Präparat HOS-098290
11
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics (e.g., neurotoxicity, QT prolongation) is unavoidable, consider
telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, (see section 4.4). the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors (e.g., tacrolimus levels may occur, as tacrolimus the next day at a
ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase >5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with and tacrolimus exposure may increase needed based on tacrolimus
without dasabuvir), >50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, ceritinib. The effect on tacrolimus blood first few days) and re-
Strong interactions have also concentrations may remain for evaluated on and after
been observed with the several days after co-administration completion of the CYP3A4
macrolide antibiotic is completed. inhibitor. Upon completion,
erythromycin. appropriate dose and dosing
frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), the prolongation) (see section 4.4). A administration. Reduce
macrolide antibiotics (e.g., rapid increase in tacrolimus level tacrolimus dose if needed (see
azithromycin), calcium may occur. section 4.2). Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol, lansoprazole,
omeprazole, the HCV
antivirals elbasvir/grazoprevir
and glecaprevir/pibrentasvir,
the CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib, crizotinib
and imatinib and (Chinese)
herbal remedies containing
extracts of Schisandra
sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-08T17:10:00Z · SHA-256 bf71e479a3104e9d8dd9aede574f2baf87c2d76cd8cc9266ee2ef92ed475dc55 · Passage 68eefd97f11d29951c1cb7e82fce1c09e7dec9a4f694ee7101cde8ef1e7bf3ae · Zeichen 3968–8645 im Abschnitt
Wechselwirkungen · Doptelet
Doptelet 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-140826 · Präparat HOS-098586
Medicinal products used in the treatment of ITP in combination with avatrombopag in clinical trials
included corticosteroids, danazol, dapsone, and intravenous immunoglobulin (IVIg). Platelet counts
should be monitored when combining avatrombopag with other medicinal products for the treatment
of ITP in order to avoid platelet counts outside of the recommended range.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): danazol (HOS-085473) dapsone (HOS-088141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-18T16:42:00Z · SHA-256 4aa299702805434ebd4ea8b3427376fdfed980657ef6db01eab3f2ed8a813c1d · Passage 81c350b273746ac8dac08de77832b4fdef1a525e9d43f4c31d9a18a9aaaf0c51 · Zeichen 2661–3030 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.